Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) CEO Jay Duker acquired 1,500 shares of the business's stock in a transaction dated Monday, March 16th. The stock was purchased at an average price of $13.15 per share, for a total transaction of $19,725.00. Following the completion of the acquisition, the chief executive officer owned 100,665 shares in the company, valued at approximately $1,323,744.75. This trade represents a 1.51% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Eyepoint Pharmaceuticals Price Performance
NASDAQ EYPT opened at $13.45 on Tuesday. The firm has a market capitalization of $1.12 billion, a P/E ratio of -4.26 and a beta of 1.72. Eyepoint Pharmaceuticals, Inc. has a 1-year low of $3.91 and a 1-year high of $19.11. The business's 50-day simple moving average is $15.24 and its 200-day simple moving average is $14.51.
Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last posted its earnings results on Wednesday, March 4th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.78) by ($0.03). Eyepoint Pharmaceuticals had a negative return on equity of 88.31% and a negative net margin of 739.39%.The business had revenue of $0.62 million for the quarter, compared to analyst estimates of $1.01 million. On average, equities research analysts expect that Eyepoint Pharmaceuticals, Inc. will post -2.13 EPS for the current fiscal year.
Institutional Trading of Eyepoint Pharmaceuticals
Several large investors have recently bought and sold shares of EYPT. State of Alaska Department of Revenue purchased a new stake in shares of Eyepoint Pharmaceuticals during the third quarter valued at approximately $50,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Eyepoint Pharmaceuticals by 51.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,023 shares of the company's stock valued at $74,000 after purchasing an additional 1,358 shares during the period. Russell Investments Group Ltd. acquired a new stake in Eyepoint Pharmaceuticals during the 3rd quarter valued at $76,000. Tower Research Capital LLC TRC grew its holdings in Eyepoint Pharmaceuticals by 218.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,700 shares of the company's stock valued at $82,000 after purchasing an additional 5,967 shares in the last quarter. Finally, California State Teachers Retirement System increased its stake in Eyepoint Pharmaceuticals by 20.6% during the 4th quarter. California State Teachers Retirement System now owns 4,654 shares of the company's stock worth $85,000 after buying an additional 794 shares during the period. Institutional investors and hedge funds own 99.41% of the company's stock.
Wall Street Analyst Weigh In
Several equities research analysts have recently issued reports on the stock. Citigroup increased their price objective on shares of Eyepoint Pharmaceuticals from $31.00 to $35.00 and gave the stock a "buy" rating in a research report on Monday, March 9th. Chardan Capital lifted their target price on shares of Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the company a "buy" rating in a report on Wednesday, March 4th. HC Wainwright upped their price target on shares of Eyepoint Pharmaceuticals from $23.00 to $30.00 and gave the stock a "buy" rating in a research report on Thursday, March 5th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Eyepoint Pharmaceuticals in a report on Thursday, January 22nd. Finally, Cantor Fitzgerald raised Eyepoint Pharmaceuticals to a "strong-buy" rating in a research report on Tuesday, November 25th. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of "Buy" and an average price target of $32.20.
Read Our Latest Analysis on Eyepoint Pharmaceuticals
About Eyepoint Pharmaceuticals
(
Get Free Report)
Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company's proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint's commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.
Eyepoint's lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
